Purpose Several medications may interact with levothyroxine (LT4) intestinal absorption or metabolism, thus reducing its bioavailability. We investigated the variability of thyroid stimulating hormone (TSH) levels and prescribed daily dosages (PDDs) of LT4 before and during potential drug-drug interactions (DDIs) in users of tablets vs. oral liquid LT4 formulations. Methods By using the Italian general practice Health Search Database (HSD), we retrospectively selected adult patients with at least one LT4 prescription from 2012 to 2015 and at least 1 year of clinical history recorded. The incident prescription of interacting medications (e.g., proton pump inhibitors, calcium or iron salts) was the index date. Analysis was carried out using a self-controlled study design. Results Overall, 3965 users of LT4 formed the study cohort (84.1% women, mean age 56 ± 16.5 years). TSH variability on the entry date was greater among liquid LT4 users than in those prescribed with tablets as shown by the difference between 75th and 25th centile, which were 3.01 and 3.8, respectively. The incidence rate ratio (IRR) for TSH variability did not differ between groups, before and during exposure to DDIs. In contrast, PDDs less likely increased during the exposure to DDI with oral liquid LT4 compared with tablets (IRR = 0.84; 95% CI: 0.77-0.92), especially in patients with post-surgical hypothyroidism (IRR = 0.75; 95% CI: 0.64-0.85). Conclusions In clinical practice, the use of oral liquid LT4 is not associated with increased PDDs, compared with tablets formulation, during exposure to DDIs. These results support the need for individualizing LT4 formulation to prescribe, especially in patients with various comorbidities and complex therapeutic regimens.
Introduction
Clinical and sub-clinical hypothyroidism are estimated to occur in about 0.4% and 4-8% of Western population, respectively [1] . The most common cause of primary hypothyroidism is low iodine dietary intake in geographical areas with severe iodine deficiency, whereas autoimmune thyroiditis, previous treatment with radioiodine or thyroidectomy are predominant in countries with mild iodine deficiency or sufficient iodine intake [1, 2] .
Nowadays, oral levothyroxine (LT4) represents the cornerstone in the treatment of hypothyroidism [1] .
LT4 is traditionally available in tablet formulation, which need to be dissolved in the acid gastric pH prior to its absorption at the levels of duodenum and jejunum [3, 4] . Approximately 70% of the LT4 contained in the tablet is Valeria Guglielmi and Alfonso Bellia equally contributed.
completely absorbed, but several conditions, such as gastrointestinal diseases (e.g. gastroenteritis, Helicobacter pylori infections, parasite colonization, lactose intolerance, intestinal ischemia, atrophic gastritis, celiac disease and inflammatory bowel diseases) [5] [6] [7] , surgical interventions at gastrointestinal level (small intestine resection or bariatric surgery) [8] [9] [10] [11] , as well as the co-administration of certain interacting foods, beverages [12] [13] [14] or drugs can impair its absorption. In particular, various frequently used medications, such as proton pump inhibitors (PPIs), ferrous sulphate, sucralfate, raloxifene, bile acid sequestrants, calcium carbonate, phosphate binders, and aluminum-containing antiacids have been demonstrated to interfere with LT4 absorption, either by increasing gastric pH (the case of PPIs) or binding LT4 into insoluble complexes (the case of calcium or iron salts) [10] . Other types of drugs reduce the bioavailability of LT4, accelerating T4 metabolism by the induction of the hepatic enzyme uridine diphosphate glucuronosyltransferase (the case of many antiepileptic drugs, such as phenobarbital, phenytoin, carbamazepine, valproate and oxcarbazepine) and/or the biliary excretion of iodothyronine conjugates (the case of rifampicin) [9] , altering the protein binding [15] or interfering with the hypothalamic-pituitary-thyroid axis function (the case of carbamazepine) [16] .
To overcome the issue of LT4 tablet absorption, new oral liquid formulations, including pre-dosed ampoules, oral drops (LT4 dissolved in glycerin and ethanol) and soft gel capsules (LT4 dissolved in glycerine within a gelatin shell), have been marketed in the recent years. These novel formulations display similar pharmacokinetic properties compared to LT4 tablets [17] , and are resistant to gastric pH variations and are characterized by higher bioavailability [18] [19] [20] . These findings have been confirmed by recent clinical studies reporting significant reductions of TSH levels [21] [22] [23] [24] [25] and measurement frequency (as proxy of clinical efficacy) in patients switching from tablets to oral liquid LT4 formulations [26] in the absence of malabsorption or drug interference. In addition, oral liquid solutions of LT4, not requiring dissolution and speeding up the absorption as compared to tablets [17, 18, 27] , have been demonstrated to circumvent LT4 malabsorption in cases of gastrointestinal diseases [28] [29] [30] and surgery [31, 32] .
When it comes to the effects of drug-drug interactions (DDIs) during LT4 therapy, few observational studies in clinical practice have been carried out so far. Furthermore, those studies were mostly limited to case series [33] or small groups of patients [22, 34] in specific settings and/or medical conditions [35] or healthy volunteers [36, 37] , thus not adequately representing the general population.
Therefore, in light of the large use of concurrent therapies interfering with LT4 bioavailability and the limited real-world data on LT4 liquid formulations in Italy, the present study aimed to analyze the Italian general practice patients exposed to tablets vs. liquid formulation LT4, in terms of variation of TSH level and prescribed daily dosages (PDDs) of LT4, as tablet and liquid formulation, before and during potential DDIs, using the Italian Health Search IMS Health Longitudinal Patient Database (HSD) [38, 39] .
Materials and methods

Data source
The study was conducted using the Italian general practice Health Search IMS Health Longitudinal Patient Database (HSD). This data source is formed by a network of approximately 1000 general practitioners (GPs) from all over Italy who voluntarily electronically register clinical patients' data from their routine clinical practice and attend training programs related to data entry. To be considered eligible for epidemiological studies, GPs need to be consistent with "up-to-standard" quality criteria including accuracy of coding, prevalence of selected diseases, rates of mortality, and years of recording. For the present study we identified 800 GPs, homogeneously distributed across all Italian areas, whose data entries fulfilled quality criteria and cover an overall population of almost 1.3 million of patients.
The HSD contains anonymized clinical data (diagnoses, patient referrals, hospital admissions, and clinical investigations' results) and prescription data (drug name, prescription date, number of days' supply) for all the medications which are reimbursed by the National Health System (NHS). Data within the HSD is coded using internationally recognized codes such as the Anatomical Therapeutic Chemical (ATC) classification system for drugs and the 9th version of the International Classification of Disease, Clinical Modification (ICD-9-CM) for medical diagnoses. The reliability of HSD for conducting clinical research has been demonstrated elsewhere [40] [41] [42] [43] .
Study population
We identified all patients aged 18 years or older being prescribed with any formulation of LT4 (ATC: H03AA01) between 1st January 2012 and 30th June 2015, time frame selected on the basis of oral liquid formulations availability in the market. The date of the LT4 prescription being registered during the enrollment period was considered the study entry date. Patients were considered eligible whether they had at least 1 year of clinical history recorded in HSD before the entry date, and were excluded if they were prescribed one of the drugs which may interact with LT4 (see the section 'Exposure assessment') before the entry date, had a diagnosis of cancer, had no TSH measurements along with a follow-up shorter than 45 days (so including 15 days of latency period, see 'Exposure assessment') after being prescribed with the interacting drug. The date of the first prescription for a potentially interacting drug was considered the study index date. Eligible patients were therefore followed up until the detection of exclusion criteria reported above, being transferred out, death, or end of data availability (30th June 2016), whichever came first.
Exposure assessment
The exposure was operationally assessed as the concurrent prescription of LT4 with potentially interacting drugs such as proton-pump inhibitors (PPIs) (ATC: A02BC*), calcium carbonate (A12AA04), aluminum hydroxide and magnesium hydroxide (A02AD01), sucralfate (A02BX02), orlistat (A08AB01), ferrous sulphate (B03AA07), cholestyramine (C10AC01), sevelamer (V03AE02), which are able to impair absorption of levothyroxine, and carbamazepine (N03AF01), phenytoin (N03AB02), phenobarbital (N03AA02), estrogens (G03C*) and raloxifene (G03XC01), which might alter both binding to plasmatic proteins and metabolism of LT4. In line with prior investigations, we excluded estrogen-progestin combinations because the pharmacological effects of one hormone on TSH may be counter-balanced by the other [44] , potentially leading to unexpected TSH fluctuations. We also excluded medications with proven minor clinical relevance [45, 46] .
Outcome assessment
We investigated how the variation of TSH levels (mIU/L) and Prescribed Daily Doses (PDDs) of tablet or liquid oral formulations of LT4 was modified by concomitant prescription with potentially interacting drugs. Both outcomes were measured at least 15 days after the co-prescription of the potentially interacting drugs (i.e. index date plus at least 15 days) in order to have a biologically plausible timeframe for a pharmacological interaction to take place [45] .
Data analysis
A pre-post analysis was carried out using a self-controlled study design. We employed generalized linear latent models for data pairs, for which we adopted gamma and Poisson distribution for TSH levels and PDDs, respectively. Every model comprised a two-level variable concerning prescriptions of tablet or oral liquid levothyroxine formulations, and another two-level variable defining the pre-post potential drug-drug interaction phase. By doing so, we were able to compare tablet vs. oral liquid formulation within pre-or during potential drug interaction (post-phase) by including in the model an interaction term, composed of pre-post interaction phase and formulation variables. The multivariable model therefore showed the effect on TSH levels exerted by co-prescription of tablet vs. oral liquid LT4 formulation at baseline (pre-phase), while what occurred in the post-phase was assessed by combining the aforementioned interaction term with the variable coding the pre-post interaction phase. Prescription of tablet formulations was the reference category for every analysis.
Since this was a self-controlled study, patient data before and during the potential drug-drug interaction were compared with regards to the outcome over the same length of the study periods. For instance, for a patient with a 6-month follow-up after the index date (i.e., censored after 6 months), the outcome was measured during the 6 months before the index date.
Multivariate model was estimated adjusting by tertile categories of serum TSH levels and therapeutic indication for LT4 use, as well as for potential confounders which had been operationally identified before or on the entry date. They included alcohol abuse or alcohol-related disease, last recorded smoking status before the entry date (smoker, exsmoker, non-smoker), last recorded body mass index (BMI) before the entry date for patients >20 Kg/m 2 , ICD-9-CM reported diagnosis of cardiovascular diseases, rheumatoid arthritis, liver failure/cirrhosis, chronic kidney disease, depression, gastrointestinal diseases related to malabsorption disorders (Crohn's disease, ulcerative colitis, celiac disease).
As secondary analysis, we reran the model after stratification by therapeutic indication of LT4. This is because the needed dosages of LT4 replacement therapy can be affected in some ways by the underlying cause of hypothyroidism (e.g. patients who underwent thyroid surgery are not influenced by the residual thyroid function as otherwise occurs in other forms of primary hypothyroidism). Table 1 shows baseline demographics and clinical characteristics of 3965 patients who received at least one LT4 dispensing during the years 2012-2015, stratified by LT4 formulation (tablet, liquid or mixed, the latter defined as randomly switching to liquid or solid formulation of LT4). Female gender was predominant (84.1%) with mean age of 56 ± 16.5 years. Most of LT4 users received tablets (N = 3643; 91.8%). Among the various causes of acquired primary hypothyroidism post-surgical hypothyroidism represented the indication for LT4 use in 23.4% of tablet users and 26.9% of liquid LT4 users. Overall, proportions of patients affected by diseases that could impair LT4 circulating levels were small and similarly distributed among groups, including alcohol abuse (0.5%), severe chronic kidney (2.1%) and hepatic (3.5%) disease, depressive disorder (15%), atrophic gastritis (0.5%), gastritis associated with Helicobacter pylori infection (0.8%), lactose intolerance, celiac disease, and intestinal malabsorption (1.2%).
Results
TSH variability on the entry date was greater in users of liquid LT4 than those prescribed with tablets (Table 1) , as shown by the Interquartile ranges (IQRs) difference (defined as75th minus 25th centile), which were 3.01 and 3.8 in patients treated with tablet and oral liquid formulations of LT4, respectively. Similarly, TSH variability at baseline was higher in patients having switched formulation when compared with tablet users.
The mostly used interacting medications encompassed proton pomp inhibitors (n = 3233 [88%]) and calcium or iron salts (n = 558 [15.2%]). Table 2 shows the results of uni-and multivariate models estimated to test the hypothesis of an association between use of different LT4 formulations and TSH variations. The incidence rate ratio (IRR) comparing users of oral liquid vs. tablet formulations in terms of TSH changes, showed nonsignificant differences, both before (adjusted IRR = (Table 2) . Similarly, nonsignificant differences were seen between mixed LT4 therapy vs. tablet users, during both period of observation (Table 2) .
Results on PDDs variation between groups are given in Table 3 . Namely, the odds of PDDs variation significantly decreased by nearly 16% in oral liquid LT4 users compared with tablet users both before (IRR = 0.84; 95% CI: 0.76-0.90) and during the DDI exposure period (IRR = 0.84; 95% CI: 0.77-0.92). Of interest, this observed difference in the rates of PDDs variability during DDIs exposure between oral liquid and tablets was even more a for all the variables listed in Table 1 pronounced in the subgroup of patients treated for postsurgical hypothyroidism (IRR = 0.75; 95% CI: 0.64-0.85).
Discussion
To our knowledge, this is the first population-based study investigating potential differences between tablets and oral liquid LT4 formulations in terms of maintenance of desired circulating levels of hormones whenever co-prescribed with potentially interacting medications. To do so, we took advantage of a sizeable sample of LT4 users (about 4000 individuals) representative of the Italian general population. Overall, we found that the use of oral liquid LT4, compared with LT4 tablets, was associated with less need for PDD increase during DDI exposure, in order to maintain TSH levels stable. During the observation period (2012-2015), LT4 liquid users initially showed an overall higher TSH variability compared to patients treated with tablets. This observation should be however interpreted with caution. Indeed, we cannot rule out, as possible explanation, that patients suffering from multiple comorbidities and treated with complex therapeutic regimens were more prone to be channeled towards LT4 liquid formulation by their physicians [47] . In this sense, the use of liquid LT4 formulation could serve as proxy for the burden of disease and multiple treatments, which inherently carry an increased risk of TSH instability, so determining a risk of channeling bias for this unexpected result in our analysis.
Reduced LT4 absorption is associated with increased TSH values, generally prompting clinicians to increase the daily dose of LT4, or otherwise to shift the patient to more bio-available formulations. In accordance, the coprescription of LT4 and potentially interacting drugs resulted in an increased dosage prescription of LT4 tablets, which likely explains the absence of a significant increase of TSH levels. Similarly, switching from tablet to liquid LT4 formulations entailed a greater increase in LT4 dosage during DDI, as already reported for drugs with a narrow therapeutic index [48] . Indeed, even small deviations in bioavailability have the potential to result in loss of TSH steadiness in some patients.
The few previous observational studies investigating the effects of DDI during LT4 therapy in real-life setting were mainly limited to local [33] and small groups of patients [22, [34] [35] [36] [37] , or did not specifically investigate the DDIs effects on variations of TSH levels [49] and LT4 prescribed dosages [50] .
In this context, our study adds real-world information collected from a primary care database, and confirms that LT4 liquid formulation can be a useful choice for patients to overcome drug-induced LT4 malabsorption and consequent need for increasing daily dosage, especially whenever diverse comorbidities are present and other potentially interfering medications are taken by patients. Contrary to a previous nationwide report in which the authors analyzed HSD records on LT4 number of prescriptions during potential DDIs regardless of the type of LT4 formulation [45] , we explored the differential effects of DDIs on LT4 liquid and tablet users choosing the PDD variation as preferred outcome best reflecting the actual therapeutic regimen. Furthermore, we improved on previous work, taking into account a number of confounders that may variously interfere with treatment effect on TSH variability, such as age, gender and diverse comorbidities, along with performing a statistical analysis which accounts for dependent pairwise data [39] . Finally, our design minimizes the impact of selection and recalls bias given that clinical data included in our database are prospectively recorded [51] .
This study has limitations as well. First, the analysis is based on prescriptions data, so that we cannot ascertain whether the drugs were actually taken by patients. However, differences in the adherence to LT4 therapy between formulations have not been so far reported, reason why the risk of misclassification would have been non differential between the compared groups. As such, the statistically significant differences we captured between groups are reassuring [52] . Second, we included only patients treated with LT4 for acquired primary hypothyroidism due to various causes including thyroidectomy. Nevertheless, the lower probability to increase the PDDs of oral liquid LT4 during DDIs exposure resulted independent of the underlying diagnosis. In addition, subgroup analysis revealed these inter-groups differences were more pronounced in individuals with post-surgical hypothyroidism, namely a clinical condition in which the thyroid hormone replacement therapy is not influenced by the residual thyroid function as possibly occurs in other forms of primary hypothyroidism. Finally, since soft gel capsules are not covered by National Health Service and our analysis did not take into account LT4 prescriptions privately purchased, exposure misclassification for newer formulations may be larger than that for tablets. However, we believe this risk of misclassification is quite low on our study (17 prescriptions out of 1012 (1.7%) for liquid formulations), since the number of these prescriptions was negligible.
In conclusion, these real-world data from primary care setting can support the use of LT4 liquid formulations in patients with hypothyroidism in order to overcome druginduced LT4 malabsorption. Using of these formulations may foster TSH stability, especially in individuals with comorbidities undergoing complex therapeutics regimens. In addition, with the reduced rates of TSH variability and need for daily dosage increase, patients are actually more protected against the risk of exposure to excessive dose of replacement therapy, whenever the interacting drugs are discontinued. This is of particular relevance in patients with or at risk of coronary artery disease, arrhythmias, and bone fractures [53, 54] . Therefore, since optimization of LT4 replacement therapy plays a key role in the successful management of hypothyroidism, in the scenario of diverse LT4 formulations availability, clinicians should carefully consider these findings to tailor patients therapy whenever co-prescription of LT4 and potentially interacting drugs is needed.
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